[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Hill A, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D, McKeage MJ: Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer; 2010;10:451
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
  • BACKGROUND: Platinum-based drugs, such as cisplatin and oxaliplatin, are well-known for inducing chronic sensory neuropathies but their acute and motor neurotoxicities are less well characterised.
  • Use was made of nerve conduction studies and needle electromyography (EMG) to assess motor nerve excitability in cancer patients during their first treatment cycle with platinum-based chemotherapy in this study.
  • METHODS: Twenty-nine adult cancer patients had a neurophysiological assessment either before oxaliplatin plus capecitabine, on days 2 to 4 or 14 to 20 after oxaliplatin plus capecitabine, or on days 2 to 4 after carboplatin plus paclitaxel or cisplatin, undertaken by a neurophysiologist who was blinded to patient and treatment details.
  • Patients completed a symptom questionnaire at the end of the treatment cycle.
  • Repetitive compound motor action potentials were less sensitive and less specific than spontaneous high frequency motor fibre action potentials for detection of acute oxaliplatin-induced motor nerve hyperexcitability but were present in 71% of patients (n = 7) and 32% of muscles (n = 32) on days 2 to 4 after oxaliplatin treatment.
  • CONCLUSIONS: Abnormal spontaneous high frequency motor fibre activity is a sensitive and specific endpoint of acute oxaliplatin-induced motor nerve hyperexcitability, detectable on EMG on days 2 to 4 post-treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Head and Neck Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Motor Neuron Disease / chemically induced. Neurotoxicity Syndromes / diagnosis
  • [MeSH-minor] Adult. Aged. Capecitabine. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Neurophysiology. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Feb;82(4):966-72 [10732773.001]
  • [Cites] Eur J Pharmacol. 2000 Oct 6;406(1):25-32 [11011028.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1767-74 [11919233.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13 [14523789.001]
  • [Cites] Muscle Nerve. 2004 Mar;29(3):387-92 [14981738.001]
  • [Cites] Ann Neurol. 1982 Jun;11(6):553-69 [6287911.001]
  • [Cites] N Engl J Med. 1990 Jan 11;322(2):126-7 [2152970.001]
  • [Cites] Ann Oncol. 1995 May;6(5):489-94 [7669713.001]
  • [Cites] Ann Neurol. 1995 Nov;38(5):714-22 [7486862.001]
  • [Cites] Drug Saf. 1995 Oct;13(4):228-44 [8573296.001]
  • [Cites] Muscle Nerve. 1996 Sep;19(9):1127-33 [8761268.001]
  • [Cites] Br J Pharmacol. 2005 Dec;146(7):1027-39 [16231011.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):573-84 [17625587.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6359-68 [17975148.001]
  • [Cites] J Negat Results Biomed. 2009;8:2 [19138416.001]
  • [Cites] Brain. 2009 Oct;132(Pt 10):2712-23 [19745023.001]
  • (PMID = 20731872.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2936328
  •  go-up   go-down


2. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL, Tumour and Angiogenesis Research Group: Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer; 2003 Sep 1;89(5):877-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.
  • Serum LDH levels have been correlated with poor prognosis and resistance to chemotherapy and radiotherapy in various neoplastic diseases.
  • In the present study, we established an immunohistochemical method to evaluate the LDH-5 overexpression in tumours, using two novel antibodies raised against the rat muscle LDH-5 and the human LDH-5 (Abcam, UK).
  • [MeSH-minor] Adult. Aged. Animals. Basic Helix-Loop-Helix Transcription Factors. Carbonic Anhydrases / biosynthesis. DNA-Binding Proteins / biosynthesis. Female. Humans. Hypoxia-Inducible Factor 1. Hypoxia-Inducible Factor 1, alpha Subunit. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Necrosis. Neoplasm Invasiveness. Neoplasm Staging. Neovascularization, Pathologic. Nuclear Proteins / biosynthesis. Prognosis. Rats. Survival Rate. Trans-Activators / biosynthesis. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1999 Nov 15;19(22):9821-30 [10559391.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] Radiother Oncol. 1999 Oct;53(1):49-52 [10624853.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3088-95 [10850461.001]
  • [Cites] Int J Radiat Biol. 2000 May;76(5):589-605 [10866281.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 21;1497(2):271-8 [10903432.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(19):7311-8 [10982848.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1335-40 [11100117.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):81-7 [11249054.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Int J Hematol. 2001 Apr;73(3):363-8 [11345204.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2821-8 [11387353.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2440-6 [11413536.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3751-6 [11439338.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):376-8 [11474266.001]
  • [Cites] Acta Oncol. 2001;40(4):536-40 [11504315.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6020-4 [11507045.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6517-25 [7987851.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21021-7 [7673128.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):644-9 [8600315.001]
  • [Cites] Clin Exp Metastasis. 1996 Mar;14(2):176-86 [8605731.001]
  • [Cites] Genomics. 1996 May 1;33(3):480-7 [8661007.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63 [9192621.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4089-96 [9632793.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):755-62 [9652835.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1726-31 [9667639.001]
  • [Cites] Curr Opin Genet Dev. 1998 Oct;8(5):588-94 [9794818.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803 [10098435.001]
  • [Cites] EMBO J. 1999 Apr 1;18(7):1905-14 [10202154.001]
  • [Cites] Melanoma Res. 1999 Apr;9(2):155-61 [10380938.001]
  • [Cites] Chest. 1999 Sep;116(3):760-5 [10492284.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(3):228-32 [11501779.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):4-11 [10623687.001]
  • [Cites] Mol Med Today. 2000 Jan;6(1):15-9 [10637570.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Feb;122(2):195-200 [10652389.001]
  • [Cites] Circ Res. 2000 Feb 18;86(3):312-8 [10679483.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1917-21 [10815916.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):881-90 [11556841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53 [11567808.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1145-50 [11583198.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):437-47 [11693903.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3399-403 [11705854.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):547-50 [11801751.001]
  • [Cites] Angiogenesis. 2001;4(1):71-7 [11824381.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4317-24 [11908686.001]
  • [Cites] Med Oncol. 2001;18(4):243-59 [11918451.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] Respirology. 2002 Jun;7(2):99-102 [11985730.001]
  • [Cites] J Endocrinol. 2002 May;173(2):335-43 [12010641.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1192-202 [12128120.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):453-8 [12496469.001]
  • [Cites] Lab Invest. 1986 May;54(5):574-8 [3702345.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Hepatology. 1991 Jul;14(1):150-7 [2066063.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • (PMID = 12942121.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hif1a protein, rat; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Isoenzymes; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / endothelial PAS domain-containing protein 1; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 5; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2394471
  •  go-up   go-down


3. Eiseman JL, Brown-Proctor C, Kinahan PE, Collins JM, Anderson LW, Joseph E, Hamburger DR, Pan SS, Mathis CA, Egorin MJ, Klecker RW: Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. Clin Cancer Res; 2004 Oct 1;10(19):6669-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
  • PURPOSE: In colorectal, breast, and head and neck cancers, response to 5-fluorouracil is associated with low expression of thymidylate synthase.
  • These studies were designed to evaluate FAU as a potential therapeutic and diagnostic probe.
  • Four hours after [3H]-FAU dosing, tissue distribution of total radioactivity and incorporation of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) 5-methyluracil (FMAU), derived from thymidylate synthase activation of FAU, into tumor DNA was measured.
  • Positron emission tomography (PET) images were obtained for 90 minutes after injection of [18F]-FAU.
  • At 240 minutes, radioactivity derived from [3H]-FAU was approximately 2-fold higher in tumors than in skeletal muscle.
  • At times up to 90 minutes, PET imaging detected only small differences in uptake of [18F]-FAU between the tumor types.
  • Fluorine-18 in skeletal muscle was higher than in tumor for the first 90 minutes and plateaued earlier, whereas [18F] in tumor continued to increase during the 90-minute imaging period.
  • CONCLUSIONS: These results for FAU incorporation into DNA in vitro and in vivo further support clinical evaluation of FAU as a therapeutic agent in tumors with high concentrations of thymidylate synthase that are less likely to respond to 5-fluorouracil treatment.
  • [MeSH-major] Arabinofuranosyluracil / analogs & derivatives. Arabinofuranosyluracil / pharmacokinetics. Colorectal Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. DNA, Neoplasm / metabolism. Female. HT29 Cells. Humans. Mice. Mice, SCID. Positron-Emission Tomography. Thymidylate Synthase / metabolism. Time Factors. Tissue Distribution. Tritium

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475457.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P30CA47904
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil; 0 / DNA, Neoplasm; 10028-17-8 / Tritium; 3083-77-0 / Arabinofuranosyluracil; EC 2.1.1.45 / Thymidylate Synthase; IN51MVP5F1 / Clevudine; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, Fukuda H: FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging; 2004 Apr;31(4):590-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
  • In advanced head and neck cancer, an organ-sparing approach comprising radiation therapy combined with intra-arterial chemotherapy has become an important technique.
  • However, the high incidence of residual masses after therapy remains a problem.
  • In this study, we prospectively evaluated the use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) delayed imaging for the detection of recurrence of head and neck cancer after radio-chemotherapy, and compared the FDG-PET results with those of magnetic resonance imaging (MRI) or computed tomography (CT).
  • Forty-three lesions from 36 patients with head and neck cancer suspected to represent recurrence after radio-chemotherapy (median interval from therapy, 4 months) were studied.
  • Three of six patients with false positive findings had post-therapy inflammation.
  • Receiver operating characteristic (ROC) analysis showed that retrospective evaluation with the standardised uptake ratio yielded the best results (sensitivity 87.5%, specificity 81.5%), followed by visual interpretation and then the tumour/neck muscle ratio.
  • An FDG-PET delayed imaging protocol yielded significantly better results for the detection of recurrence of head and neck cancer after radio-chemotherapy than MRI/CT.
  • [MeSH-major] Fluorodeoxyglucose F18. Head and Neck Neoplasms / diagnostic imaging. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / therapy. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drug Therapy / methods. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography / methods. Radiotherapy / methods. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 1999 Oct;26(10 ):1345-8 [10541835.001]
  • [Cites] J Neurol Sci. 1995 Sep;132(1):20-7 [8523026.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4 Suppl 8):34-8 [10952436.001]
  • [Cites] J Nucl Med. 1997 Feb;38(2):280-7 [9025756.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Ann Nucl Med. 1997 Nov;11(4):307-13 [9460522.001]
  • [Cites] Head Neck. 2001 Nov;23 (11):942-6 [11754497.001]
  • [Cites] Eur J Nucl Med. 2001 Jun;28(6):696-703 [11440029.001]
  • (PMID = 14722678.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Werner JA, Dünne AA: Value of neck dissection in patients with squamous cell carcinoma of unknown primary. Onkologie; 2001 Feb;24(1):16-20
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of neck dissection in patients with squamous cell carcinoma of unknown primary.
  • Lymph node metastases of cancer of an unknown primary (CUP syndrome) are responsible for 3-5% of the malignant diseases in the head and neck area.
  • For a curative approach modified radical neck dissection combined with postoperative radiation therapy with or without chemotherapy should be considered in N1-N3 lymph node status.
  • A radical neck dissection with postoperative radiation therapy should only be approved in cases of infiltration of the internal jugular vein, the accessory nerve and/or the sternocleidomastoid muscle.
  • The different prognosis of patients with upper cervical and lower cervical lymph nodes should influence the indication and the extent of a neck dissection in the contralateral N0 neck.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Lymphatic Metastasis / pathology. Neck Dissection. Neoplasms, Unknown Primary / surgery
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441275.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 37
  •  go-up   go-down


6. Motsch C, Schmitt J, Roessner A, Mittler U, Freigang B: [Desmoid tumors of the head and neck]. Laryngorhinootologie; 2007 Jul;86(7):524-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumors of the head and neck].
  • Desmoid tumors of the head and neck, also known as aggressive fibromatoses, are rare.
  • They are soft tissue neoplasms arising from musculoaponeurotic structures and characterized of locally aggressive infiltration and recurrences.
  • MRI is the first choice in the preoperative evaluation of neck desmoids.
  • We describe the successful treatment of desmoid tumors in two cases (M. sternocleidomastoideus, M. levator scapulae).
  • [MeSH-major] Fibromatosis, Aggressive / diagnosis. Head and Neck Neoplasms / diagnosis. Muscle Neoplasms / diagnosis. Neck Muscles
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Cranial Nerve Injuries / diagnosis. Cranial Nerve Injuries / prevention & control. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Monitoring, Intraoperative. Neck Dissection. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Postoperative Complications / diagnosis. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219337.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Feng AC, Wu MC, Tsai SY, Chan KY, Cheng SH, Wang A, Chen SS, Jian JJ, Terng SD, Huang AT: Prevertebral muscle involvement in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1026-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevertebral muscle involvement in nasopharyngeal carcinoma.
  • PURPOSE: The purpose of this study is to evaluate the prevalence and prognostic significance of prevertebral muscle involvement in patients with nasopharyngeal carcinoma (NPC).
  • METHODS AND MATERIALS: Between July 1990 and December 2001, 521 newly diagnosed patients with NPC treated at Koo Foundation Sun Yat-Sen Cancer Center (KF-SYSCC) were examined with magnetic resonance imaging (MRI) for evidence of prevertebral muscle involvement before treatment.
  • All patients received radiotherapy with or without chemotherapy.
  • The association between clinical prevertebral muscle involvement and posttreatment outcomes (overall survival, locoregional recurrence, and distant metastasis) were evaluated using Cox regression model to adjust for other prognostic factors.
  • RESULTS: Of 521 patients treated at KF-SYSCC, 181 (35%) patients were found to have prevertebral muscle involvement, one-third in those with Stage II/III tumors and two-thirds in those with Stage IV tumor.
  • In multivariate analysis accounting for all previously known prognostic factors, prevertebral muscle invasion was associated with an increased risk for any recurrence (adjusted relative risk, 2.01; p<0.001), locoregional recurrence (adjusted relative risk, 2.69; p<0.001), and distant metastasis (adjusted relative risk, 2.25; p<0.001), and with a borderline significant increased risk for overall survival (adjusted relative risk, 1.44; p=0.10).
  • CONCLUSIONS: Prevertebral muscle involvement is an independent prognostic factor for NPC recurrence.
  • [MeSH-major] Muscle Neoplasms / pathology. Muscle, Skeletal / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cervical Vertebrae. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neck Muscles / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682150.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Morawietz L, Kuhnen C, Katenkamp D, Le Coutre P, Ladhoff A, Petersen I: Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma. Virchows Arch; 2005 Dec;447(6):990-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma.
  • Myofibrosarcoma is a rare neoplasm that occurs mainly in the head and neck region and extremities of middle-aged patients.
  • A major spindle cell component was observed being positive for smooth-muscle actin, calponin, and vimentin, while stainings for desmin, h-caldesmon, alkaline phosphatase (ALK), and extensively studied cytokeratins were negative.
  • Shortly after resection of the primary tumor, the patient showed multiple distant metastases in the contralateral lung, the mediastinal lymph nodes, the left adrenal gland, and the pectoral and deltoid muscle, which responded well to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Pathologe. 2003 Mar;24(2):128-35 [12673503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Dermatol. 2001 Jul;28(7):383-7 [11510507.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):331-40 [8085557.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12 ):1501-7 [11717539.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):611-22 [8122327.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):33-42 [12377411.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):459-69 [11905413.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):393-4; author reply 394-6 [11981942.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):489-96 [9130998.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • (PMID = 16158184.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Cruz AA, Leite LV, Chahud F, Neder L, Tone LG, Valera ET, Elias J Jr: T-cell sinonasal lymphoma presenting as acute orbit with extraocular muscle infiltration. Ophthal Plast Reconstr Surg; 2004 Nov;20(6):473-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell sinonasal lymphoma presenting as acute orbit with extraocular muscle infiltration.
  • Orbital computed tomography showed progressive right extraocular muscle enlargement.
  • One biopsy specimen showed extensive tissue necrosis and an infiltrate of atypical cells with pleomorphic nuclei within the walls of blood vessels.
  • Chemotherapy for T-cell non-Hodgkin lymphoma was initiated, but the patient's status deteriorated and the child died of respiratory insufficiency, sepsis, and central nervous system infection.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15599254.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM: A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer; 2005 Mar;41(4):523-30
Hazardous Substances Data Bank. LOVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
  • Squamous cell carcinomas of the head and neck (HNSCC) and of the cervix (CC) are particularly sensitive to the apoptotic effects of lovastatin in vitro.
  • Dose-limiting toxicity (DLT) consisting of reversible muscle toxicity was seen at 10 mg/kg/day x 14 days.
  • One patient achieved SD and clinical benefit for 14 months on study and a further 23 months off treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage. Lovastatin / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737556.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


11. Zengel P, Mees K, Müller-Schunk S, Suckfüll M: [An unusual case of carotid arrosion bleeding]. HNO; 2009 Nov;57(11):1203-8
MedlinePlus Health Information. consumer health - Foreign Bodies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a rare complication in patients with cancer of the head and neck after radiochemotherapy.
  • We report the case of a 65-year-old man who suffered from cancer of the tonsils (pT2pN1M0) and was treated in 1987 with surgery and local chemotherapy.
  • The patient was re-operated and during surgery the tip of a catheter was found in the external carotid artery, obviously a remnant from a catheter for intra-arterial chemotherapy.
  • The tip was removed, the defect closed and covered with a pectoralis major muscle flap.
  • [MeSH-major] Carotid Artery Diseases / etiology. Carotid Artery, External. Catheters, Indwelling. Cutaneous Fistula / etiology. Foreign Bodies / etiology. Hemorrhage / etiology. Infusions, Intra-Arterial / instrumentation. Postoperative Complications / etiology. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / surgery. Vascular Fistula / etiology
  • [MeSH-minor] Aged. Angiography, Digital Subtraction. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Neck Dissection. Neoplasm Staging. Radiotherapy, Adjuvant. Reoperation. Stents. Surgical Flaps. Tonsillectomy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1958 Jan 18;1(7012):141 [13503235.001]
  • [Cites] Laryngoscope. 1995 Oct;105(10 ):1086-92 [7564841.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):760-4 [2769046.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Sep;33(9):1241-6 [16969018.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 May;17 (5):843-52 [8733956.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):975-81 [12748106.001]
  • [Cites] Rev Esp Cardiol. 1996 Jan;49(1):41-7 [8685511.001]
  • [Cites] Am J Surg. 1974 Dec;128(6):722-7 [4432992.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Apr;132(4):667-8 [15806069.001]
  • [Cites] Acta Anaesthesiol Scand. 1989 Oct;33(7):565-7 [2683544.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12 (2):110-5 [15167047.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jun-Jul;20(6):1069-77 [10445446.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):15-9 [9006498.001]
  • [Cites] AJR Am J Roentgenol. 1978 Mar;130(3):541-8 [415566.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1987 Sep;66(9):460-4 [3683039.001]
  • [Cites] Jpn J Clin Oncol. 2006 Dec;36(12):822-6 [17060408.001]
  • (PMID = 19847380.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Antoniades K, Lazaridis N, Vahtsevanos K, Hadjipetrou L, Antoniades V, Karakasis D: Treatment of squamous cell carcinoma of the anterior faucial pillar-retromolar trigone. Oral Oncol; 2003 Oct;39(7):680-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of squamous cell carcinoma of the anterior faucial pillar-retromolar trigone.
  • Cancer of the anterior faucial pillar-retromolar trigone is an uncommon head and neck tumor, which has historically been shown to be associated with poor prognosis.
  • In this retrospective study, we reviewed our experience with primary surgery followed by postoperative radiation therapy in order to determine the impact of our treatment protocols on patients' outcome.
  • Surgical excision of the primary lesion and ipsilateral neck dissection were performed in all patients.
  • Reconstruction was accomplished using masseter muscle flap or tongue flap.
  • Postoperatively, most patients (90%) received radiation therapy (51-58 Gy) to the primary side and neck.
  • Adjuvant chemotherapy was offered if histologic signs of aggressive behavior were identified.
  • Metastatic disease was demonstrated in 78% of ipsilateral neck nodes.
  • The reconstruction of the deficit of the anterior faucial pillar-retromolar area with masseter muscle flap is a reliable, safe and absolutely functional method.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prognosis. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12907207.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Collin AC, Chekaroua K, Delaporte T, Droz JP, Peix JL, Delay E: [Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report]. Ann Chir; 2006 Dec;131(10):631-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chirurgie d'exérèse élargie et reconstruction cervicale pour cancer anaplasique de la thyroïde. A propos d'un cas.
  • The goal of this study was to present the case of a patient who underwent a multimodal treatment and to analyze prognosis factors.
  • The initial surgical procedure was a total thyroidectomy extended to the anterior cervical skin associated to bilateral neck dissection.
  • Management was then supplemented by radiotherapy and chemotherapy.
  • CONCLUSION: Anaplastic carcinoma is one of more aggressive neoplasm affecting humans.
  • This case report suggests that multimodality therapy, including surgery, chemotherapy and radiotherapy may offer hope for long-term survival.
  • [MeSH-major] Carcinoma / surgery. Neck Dissection / methods. Reconstructive Surgical Procedures / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Muscle, Skeletal / transplantation. Radiotherapy, Adjuvant. Skin Transplantation / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824476.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Chigurupati R, Alfatooni A, Myall RW, Hawkins D, Oda D: Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases. Oral Oncol; 2002 Jul;38(5):508-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is an aggressive malignant skeletal muscle neoplasm arising from embryonal mesenchyme.
  • It accounts for over 50% of all pediatric soft tissue sarcomas.
  • The head and neck region is the most common site for this tumor in children.
  • Three of the four cases were alveolar RMS and one was botryoid sub-type of embryonal RMS.
  • Three patients were treated with a combination of surgery, chemotherapy and radiation, while the patient with botryoid RMS was treated with surgery and chemotherapy only.
  • We discuss the current management, diagnosis, biological behavior, histopathology, prognosis and survival of head and neck RMS in neonates and young children.
  • [MeSH-major] Facial Neoplasms / therapy. Mouth Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110348.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


15. Adigun IA, Rahman GA: A review of soft tissue sarcoma. Niger J Med; 2007 Apr-Jun;16(2):94-101
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of soft tissue sarcoma.
  • BACKGROUND: Soft tissue sarcomas (STS) are a heterogeneous group of rare tumours that arise predominantly from the embryonic mesoderm.
  • They present most commonly as an asymptomatic mass originating in an extremity but can occur anywhere in the body, particularly the trunk, retroperitoneum, or the head and neck.
  • Tru-cut biopsy is a safe, accurate and economical procedure for diagnosing STS.
  • Enough tissue is usually obtained for use in several diagnostic tests such as electron microscopy and cytogenetic analysis.
  • With the advent of Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA), tumours can easily be delineated from muscle groups, bone and neurovascular structures.
  • Surgery remains the main potentially curative therapy for STS.
  • In the last two decades, the role of adjuvant radiotherapy has revolutionized the treatment from a situation where amputation was the standard treatment for extremity STS to the present time where limb sparing surgery is appropriate in more than 90% of patients.
  • Postoperative adjuvant chemotherapy significantly improves the overall and disease free survival for patients with large size and high grade sarcomas.
  • CONCLUSION: Optimal results of treatment require multidisciplinary interaction between the referring practitioner, the treating surgeon, the pathologist, the radiotherapist and the chemotherapist.
  • [MeSH-major] Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Nigeria / epidemiology. Prognosis. Risk Assessment. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694759.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 75
  •  go-up   go-down


16. Chi AC, Barnes JD, Budnick S, Agresta SV, Neville B: Rhabdomyosarcoma of the maxillary gingiva. J Periodontol; 2007 Sep;78(9):1839-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rhabdomyosarcoma is a malignant neoplasm of primitive mesenchyme exhibiting skeletal muscle differentiation.
  • Oral rhabdomyosarcoma is rare and accounts for only 0.04% of all head and neck malignancies.
  • The tissue was boggy and tender on palpation.
  • The patient was treated by surgical resection with postoperative chemotherapy and radiation.
  • The patient had no evidence of disease at a follow-up examination 1 month after completion of therapy.
  • Over several decades, a multidisciplinary treatment approach that includes surgical removal if resectable, in combination with multiagent chemotherapy and possibly radiation therapy, has improved survival rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760557.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


17. Alaggio R, Ninfo V, Rosolen A, Coffin CM: Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am J Surg Pathol; 2006 Mar;30(3):388-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas in the first year of life are rare, and the most common sarcomas in infancy are embryonal rhabdomyosarcoma, Ewing sarcoma/primitive neuroectodermal tumor, congenital infantile fibrosarcoma, and primitive sarcomas such as undifferentiated sarcoma.
  • PMMTI occurred in 6 infants, 3 of whom had a congenital presentation of a soft tissue mass.
  • The tumors occurred on the trunk, extremities, and head and neck.
  • Immunohistochemically, the tumors displayed diffuse reactivity for vimentin and no reactivity for smooth muscle actin, muscle specific actin, desmin, S-100 protein, or myogenin.
  • Three patients had recurrences or metastasis treated with a combination of surgery and chemotherapy.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Dermatofibrosarcoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / pathology. Nerve Sheath Neoplasms / pathology. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538060.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETV6-NTRK3 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


18. Fenton S, Kemp EG, Harnett AN: Screening for ophthalmic involvement in asymptomatic patients with metastatic breast carcinoma. Eye (Lond); 2004 Jan;18(1):38-40
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recognition and early treatment of both ocular metastases and ocular manifestations of metastatic breast carcinoma are important in maximising the quality of life in this group of palliative patients.
  • RESULTS: The median time from diagnosis of breast carcinoma to ophthalmic screening was 5 years (range 6 months-23 years).
  • Four patients (5.8%) had ophthalmic manifestations of metastatic breast carcinoma and a further two had ocular complications of treatment.
  • One patient had a restrictive motility problem from a metastatic deposit to her lateral rectus muscle and another had corneal punctate epitheliopathy secondary to a seventh nerve palsy.
  • A further patient had coarse nystagmus from cerebellar metastases and the final patient of the four had a Horner's syndrome from metastases in the neck.
  • In addition, two patients had symptomatic dry eyes whose onset coincided with commencement of chemotherapy.
  • [MeSH-minor] Adult. Aged. Eye Diseases / etiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pilot Projects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eye (Lond). 2004 Jan;18(1):1-2 [14707955.001]
  • (PMID = 14707963.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G: Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol; 2008 Dec;33(4):341-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
  • In this article the Authors review the pathology, epidemiology, clinical presentation, diagnosis and treatment options of ATC.
  • ATC may arise de novo, but in most cases it develops from a pre-existing WDTC, especially the follicular subtype.
  • Most ATC patients complain of local compressive symptoms, such as dysphagia, dysphonia, stridor and dyspnea in addition to neck pain and tenderness; in over 70% of the patients the tumor infiltrates surrounding tissues, such as fat, trachea, muscle, esophagus, and larynx.
  • Computed tomography (CT) scan and magnetic resonance imaging (MRI) are useful for defining the local extent of disease and for identifying distant metastases, as is also positron-emission tomography (PET) with [(18)F]FDG.
  • Treatment of ATC has not been standardized because it is not clear whether or not therapy is effective in prolonging survival; most patients die within six momths from diagnosis, primarily because of asphyxiation caused by local tumor invasion.
  • When employed alone, surgery, radiotherapy, or chemotherapy are seldom adequate to achieve overall control of the disease, but a combination of these treatments may improve local control.
  • Surgical treatment of local disease offers the best opportunity for prolonged survival if the tumor is intrathyroidal.
  • Some favourable results have recently been reported with newly developed chemotherapy agents and hyper-fractioned radiation therapy.
  • Gene therapy is under investigation.
  • Although very rare, ATC is a highly aggressive tumor that belongs to the group of killer tumors with median survival time not longer than 6-8 months.
  • Surgery, chemotherapy and radiotherapy are the conventional therapeutic strategies performed in the attempt to improve survival.
  • Unfortunately, very often they do not succeed any clinical benefit but only palliative RESULTS: New therapeutic strategies based on molecular approaches are desirable.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Age Distribution. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Humans. Incidence. Italy / epidemiology. Magnetic Resonance Imaging. Neoplasm Staging. Positron-Emission Tomography / methods. Prevalence. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Sex Distribution. Thyroidectomy. Tomography, X-Ray Computed


20. Kurtkaya-Yapícíer O, Scheithauer BW, Dedrick DJ, Wascher TM: Primary epithelioid sarcoma of the dura: case report. Neurosurgery; 2002 Jan;50(1):198-202; discussion 202-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite isolated reports of epithelioid sarcomas arising in the head and neck region, these lesions have not been described previously, to our knowledge, in the central nervous system.
  • As visualized on magnetic resonance imaging studies, the 4.5-cm tumor focally traversed the cranium to penetrate the galea, the temporal muscle, and subcutaneous tissue.
  • INTERVENTION: Despite gross total removal and postoperative radiotherapy (59 Gy), a large recurrence was noted 5 months after surgery.
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Microscopy, Electron. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11852861.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Sbeity S, Abella A, Arcand P, Quintal MC, Saliba I: Temporal bone rhabdomyosarcoma in children. Int J Pediatr Otorhinolaryngol; 2007 May;71(5):807-14
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric age group.
  • The twofold objective of this study is to illustrate the clinical presentation, management, and prognosis of this malignant striated muscle tumor, and to compare these results with previously reported series.
  • METHODS: A retrospective study was conducted of patients diagnosed and treated for rhabdomyosarcoma of the head and neck at Saint Justine Hospital, a tertiary pediatric center, between 1970 and 2005.
  • A thorough review of medical and surgical charts was performed to obtain demographic, clinical, paraclinical, and therapeutic data, which were subsequently analyzed and compared to published results.
  • RESULTS: Thirty-nine patients with rhabdomyosarcoma of the head and neck region were identified, among which only six children had temporal bone rhabdomyosarcoma.
  • The mean age at the time of diagnosis was 4.15 years.
  • All patients except two received combined chemotherapy and radiotherapy as treatment.
  • A high index of suspicion should be raised in the context of otitis media that is unresponsive to ordinary medical treatment.
  • A biopsy is hence recommended in the presence of polyps in the external auditory canal that are resistant to medical treatment.
  • Early diagnosis and the adoption of multimodal therapy offer the best outcome.
  • [MeSH-minor] Adolescent. Child, Preschool. Chronic Disease. Female. Humans. Male. Neoplasm Staging. Otitis Media / etiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346806.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


22. Mentzel T, Kuhnen C: Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases. Virchows Arch; 2006 Nov;449(5):554-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four neoplasms arose on the lower extremities and one case each on the forearm, the lateral aspect of the neck and the penis.
  • Five neoplasms were completely excised, in one incompletely excised neoplasm additional chemotherapy was given, and in one patient a biopsy was done only so far.
  • All neoplasms arose in subcutaneous and deep soft tissues with dermal involvement in one case, and the size of the neoplasms ranged from 4 to 19 cm in largest diameter.
  • In addition, five out of seven cases tested stained focally positive for alpha-smooth muscle actin.
  • In summary, spindle cell rhabdomyosarcoma represents a rare neoplasm in adulthood characterized clinically by a rather poor prognosis, and shows a broad morphological spectrum including most likely the sclerosing, pseudovascular variant.
  • [MeSH-major] Rhabdomyosarcoma / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Aug 1;98(3):571-80 [12879475.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):572-8 [17016719.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):399-408 [10666368.001]
  • [Cites] Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 [15630526.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):305-11 [10834531.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):221-30 [8434703.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):595-603 [11406662.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):215-23 [11505068.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):229-35 [1599014.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1106-13 [16006807.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1080-6 [12379755.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):64-7 [15660283.001]
  • (PMID = 17013628.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


23. Skeie GO, Romi F: Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur J Neurol; 2008 Oct;15(10):1029-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paraneoplastic myasthenia gravis (MG) is accompanied by a neoplasm, usually thymoma.
  • In patients with thymoma and a specific genetic make-up, the paraneoplastic immune response develops further in thymic remnant or peripheral lymphatic tissue.
  • The presence of a thymoma per se does not cause more severe MG.
  • Paraneoplastic MG causes a distinctive non-limb symptom profile at MG onset, characterized by bulbar, ocular, neck, and respiratory symptoms.
  • When the diagnosis of paraneoplastic MG is established, the neoplasm should be removed surgically.
  • The pharmacological treatment of paraneoplastic MG does not differ from non-paraneoplastic MG, except for tacrolimus that should be considered in difficult cases.
  • [MeSH-minor] Age of Onset. Atrophy. Autoantibodies / immunology. Autoantigens / immunology. Combined Modality Therapy. Connectin. Humans. Hyperplasia. Immunosuppressive Agents / therapeutic use. Middle Aged. Muscle Proteins / immunology. Nerve Tissue Proteins / immunology. Plasmapheresis. Prognosis. Protein Kinases / immunology. Receptors, Cholinergic / immunology. Ryanodine Receptor Calcium Release Channel / immunology. Thymectomy. Thymus Gland / pathology

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717725.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Connectin; 0 / Immunosuppressive Agents; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Cholinergic; 0 / Ryanodine Receptor Calcium Release Channel; 0 / TTN protein, human; EC 2.7.- / Protein Kinases
  • [Number-of-references] 36
  •  go-up   go-down






Advertisement